- Deep and durable responses in drug-resistant KRAS-G12C- and EGFR-mutant NSCLC - Best-in-class safety profile highlights potential for development in…
Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was well tolerated Oral FASN inhibitors offer a novel mechanism…
Pairing data-driven clinical-molecular insights with biological validation to identify relevant drug targets and confirm leads for biopharmaceutical companiesMILAN, Italy and…
June 4, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) today announced that it will repurchase up to 6 million shares to…
Figure_1 Figure 1: Clinical Remission rate observed in all-comers population and sub-population according to composite IL7R axis biomarker in CoTikiS…
LIfT BioSciences joins Bayer Co.Lab Cambridge, securing access to cutting-edge lab facilities London, 4 June 2025– LIfT BioSciences, (‘LIfT’ or…
Documents made available to the shareholders for the combined general meeting of June 25th, 2025 Nantes, June 4th, 2025, 8…
The shares in Vistin Pharma ASA (VISTN) will be traded ex dividend NOK 1.25 as from today, 04.06.2025.
Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with SMA Evrysdi offers…
Saint-Herblain (France), June 4, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company (“the Company”), today…